Lisata Therapeutics Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.96
- Today's High:
- $2.11
- Open Price:
- $1.97
- 52W Low:
- $1.96
- 52W High:
- $9.75
- Prev. Close:
- $1.97
- Volume:
- 18450
Company Statistics
- Market Cap.:
- $17.75 million
- Book Value:
- 7.128
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -23.26%
- Return on Equity TTM:
- -76.63%
Company Profile
Lisata Therapeutics Inc. had its IPO on 1999-03-01 under the ticker symbol LSTA.
The company operates in the Healthcare sector and Biotechnology industry. Lisata Therapeutics Inc. has a staff strength of 27 employees.
Stock update
Shares of Lisata Therapeutics Inc. opened at $1.97 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.96 - $2.11, and closed at $1.96.
This is a -0.51% slip from the previous day's closing price.
A total volume of 18,450 shares were traded at the close of the day’s session.
In the last one week, shares of Lisata Therapeutics Inc. have slipped by -10.09%.
Lisata Therapeutics Inc.'s Key Ratios
Lisata Therapeutics Inc. has a market cap of $17.75 million, indicating a price to book ratio of 0.3165 and a price to sales ratio of 0.
In the last 12-months Lisata Therapeutics Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-27437000. The EBITDA ratio measures Lisata Therapeutics Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lisata Therapeutics Inc.’s operating margin was 0% while its return on assets stood at -23.26% with a return of equity of -76.63%.
In Q2, Lisata Therapeutics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Lisata Therapeutics Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-9.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lisata Therapeutics Inc.’s profitability.
Lisata Therapeutics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.9017. Its price to sales ratio in the trailing 12-months stood at 0.
Lisata Therapeutics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $62.37 million
- Total Liabilities
- $4.36 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Lisata Therapeutics Inc. ended 2024 with $62.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $62.37 million while shareholder equity stood at $57.97 million.
Lisata Therapeutics Inc. ended 2024 with $0 in deferred long-term liabilities, $4.36 million in other current liabilities, 8000.00 in common stock, $-517455000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $23.69 million and cash and short-term investments were $57.63 million. The company’s total short-term debt was $160,000 while long-term debt stood at $0.
Lisata Therapeutics Inc.’s total current assets stands at $61.42 million while long-term investments were $0 and short-term investments were $33.94 million. Its net receivables were $0 compared to accounts payable of $775000.00 and inventory worth $0.
In 2024, Lisata Therapeutics Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Lisata Therapeutics Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.96
- 52-Week High
- $9.75
- 52-Week Low
- $1.96
- Analyst Target Price
- $11.83
Lisata Therapeutics Inc. stock is currently trading at $1.96 per share. It touched a 52-week high of $9.75 and a 52-week low of $9.75. Analysts tracking the stock have a 12-month average target price of $11.83.
Its 50-day moving average was $2.96 and 200-day moving average was $3.3 The short ratio stood at 1.1 indicating a short percent outstanding of 0%.
Around 1721.9% of the company’s stock are held by insiders while 933.9% are held by institutions.
Frequently Asked Questions About Lisata Therapeutics Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.